These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31810389)

  • 1. The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control.
    Gautier T; Umpierrez G; Renard E; Kovatchev B
    J Diabetes Sci Technol; 2021 Mar; 15(2):371-376. PubMed ID: 31810389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
    Blonde L; Bailey TS; Chao J; Dex TA; Frias JP; Meneghini LF; Roberts M; Aroda VR
    Adv Ther; 2019 Sep; 36(9):2310-2326. PubMed ID: 31359368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
    Davidson JA; Desouza C; Fonseca V; Frias JP; Van Gaal L; Giorgino F; Chao J; Dex TA; Roberts M; Saremi A; Leiter LA
    Diabet Med; 2020 Feb; 37(2):256-266. PubMed ID: 31365765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
    Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
    Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
    Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
    BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
    Skolnik N; Dupree RS; Johnson EL
    Curr Med Res Opin; 2017 Dec; 33(12):2187-2194. PubMed ID: 28741967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
    Handelsman Y; Chovanes C; Dex T; Giorgino F; Skolnik N; Souhami E; Stager W; Niemoeller E; Frias JP
    J Diabetes Complications; 2019 Mar; 33(3):236-242. PubMed ID: 30600136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
    Mora PF; Chao J; Saremi A; Dex TA; Roberts M; Umpierrez GE
    Endocr Pract; 2019 Nov; 25(11):1091-1100. PubMed ID: 31241362
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes.
    Pablo Frias J; Lorenz M; Roberts M; Dex T; Schmider W; Hurst W; Skolnik N
    Curr Med Res Opin; 2019 Apr; 35(4):689-695. PubMed ID: 30360647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
    Schmider W; Belder R; Lee M; Niemoeller E; Souhami E; Frias JP
    Curr Med Res Opin; 2019 Jun; 35(6):1081-1089. PubMed ID: 30550345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
    Frias J; Puig Domingo M; Meneghini L; Napoli R; Liu M; Soltes Rak E; Aroda VR
    Diabetes Obes Metab; 2018 Sep; 20(9):2314-2318. PubMed ID: 29785837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.
    Inoue M; Lorenz M; Muto H; Wesch R; Hashimoto Y
    Diabetes Obes Metab; 2019 Aug; 21(8):2001-2005. PubMed ID: 31050109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
    Goldman J; Trujillo JM
    Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
    Davies MJ; Leiter LA; Guerci B; Grunberger G; Ampudia-Blasco FJ; Yu C; Stager W; Niemoeller E; Souhami E; Rosenstock J
    Diabetes Obes Metab; 2017 Dec; 19(12):1798-1804. PubMed ID: 28432746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
    Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
    Terauchi Y; Yabe D; Kaneto H; Amano A; Baxter M; Watanabe D; Watada H; Inagaki N
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():35-47. PubMed ID: 33404200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
    Giorgino F; Caruso I; Napoli R
    Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
    Risovic I; Dumanovic MS; Bojic M; Djekic D
    BMC Endocr Disord; 2023 Feb; 23(1):28. PubMed ID: 36726134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
    Meier JJ; Rosenstock J; Hincelin-Méry A; Roy-Duval C; Delfolie A; Coester HV; Menge BA; Forst T; Kapitza C
    Diabetes Care; 2015 Jul; 38(7):1263-73. PubMed ID: 25887358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.